Application of GDF15 inhibitor targeting TCF19 in preparation of medicine for treating liver cancer
By using a GDF15 inhibitor targeting TCF19 and binding to the GDF15 promoter, the expression of the GDF15 gene is inhibited at the transcriptional level, thus solving the problem of GDF15 expression in liver cancer cells and achieving high efficiency and selectivity in liver cancer treatment.
Patent Information
- Application Number
- CN202411104912.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
AI Technical Summary
Existing technologies are unable to effectively inhibit the expression of GDF15 in liver cancer cells, leading to tumor growth and metastasis, and traditional treatment methods cause significant damage to normal tissues.
By employing a GDF15 inhibitor targeting TCF19, the expression of the GDF15 gene is inhibited at the transcriptional level through the binding of the PHD domain of TCF19 to the GDF15 promoter, thereby regulating its mRNA and protein expression.
It achieves specific inhibition of GDF15 expression in liver cancer cells, reduces damage to normal tissues, and has good molecular selectivity and therapeutic effect.
Smart Images

Figure CN118987221A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology and relates to the application of a TCF19-targeting GDF15 inhibitor in the preparation of a drug for treating liver cancer. Background Art
[0002] Tumorigenesis in the liver involves a multistage process driven by chronic inflammatory liver disease. Early dysplastic lesions arise in a disrupted tissue microenvironment and subsequently develop into early and advanced HCC lesions.
[0003] Molecular targeted therapy targets certain marker molecules overexpressed by tumor cells, selects targeted blockers, and effectively intervenes in the signal transduction pathways regulated by and closely related to the marker molecules, thereby inhibiting tumor growth, progression, and metastasis. Compared with the three traditional treatments of surgery, radiotherapy, and chemotherapy, molecular targeted therapy has better molecular selectivity, can efficiently and selectively kill tumor cells, and reduce damage to normal tissues. Research and development of liver cancer-specific target drugs are of great significance. Summary of the invention
[0004] The present invention aims to provide the use of a TCF19-targeting GDF15 inhibitor in the preparation of a drug for treating liver cancer.
[0005] To achieve the above object, the present invention adopts the following technical solutions:
[0006] The present invention provides an application of a TCF19 inhibitor in the preparation of a drug for inhibiting the expression of the GDF15 gene. The TCF19 inhibitor uses TCF19 as a target to inhibit the expression of the GDF15 gene from a transcriptional level.
[0007] Furthermore, TCF19 binds to the GDF15 promoter via its PHD domain.
[0008] Furthermore, TCF19 positively regulates the expression of GDF15 gene at both mRNA and protein levels.
[0009] Furthermore, overexpression and knockdown of TCF19 in cells can promote and inhibit GDF15 transcription, respectively; after cells overexpress TCF19, the protein level of GDF15 increases, and after knockdown of TCF19, the protein expression level of GDF15 decreases.
[0010] The present invention also provides the use of a TCF19-targeted GDF15 inhibitor in the preparation of a drug for treating liver cancer, wherein the TCF19-targeted GDF15 inhibitor inhibits the transcription of GDF15 in tumor cells by targeting TCF19.
[0011] Furthermore, TCF19 binds to the GDF15 promoter via its PHD domain.
[0012] Furthermore, TCF19 positively regulates the expression of GDF15 gene at both mRNA and protein levels.
[0013] Furthermore, overexpression and knockdown of TCF19 in cells can promote and inhibit GDF15 transcription, respectively; when cells overexpress TCF19, the protein level of GDF15 increases; when TCF19 is knocked down, the protein expression level of GDF15 decreases.
[0014] The present invention further provides a reagent for detecting the binding of TCF19 and GDF15, comprising the following detection primers:
[0015] GDF15-1-F: 5'-GCACCCTGCTTAGACTGGAA-3';
[0016] GDF15-1-R: 5′-CACAGGGCCAGACACATAGG-3′;
[0017] GDF15-2-F: 5′-TCCTATGTGTCTGGCCCTGT-3′;
[0018] GDF15-2-R: 5′-ATGTGTCATGCCTCTCTGCC-3′;
[0019] GDF15-3-F: 5′-CCTGGTGAGGAAACAGGCAT-3′;
[0020] GDF15-3-R: 5′-AGGAGAACGGGCTAGATGGA-3′;
[0021] GDF15-4-F: 5′-ATCAAGGTTGCCCTTCCTGG-3′;
[0022] GDF15-4-R: 5′-TGCCCATGGGATTTCCTCTC-3′;
[0023] GDF15-5-F: 5'-AGCCTTTGACCCAACCAAA-3';
[0024] GDF15-5-R: 5'-ATGAGGACACCATTCCAGCC-3'.
[0025] Preferably, an internal reference primer is also included:
[0026] GAPDH-1-F: 5'-GGTGGTCTCCTCTGACTTC-3';
[0027] GAPDH-1-R: 5'-CTCTTCCTCTTGTGCTCTTG-3'.
[0028] The present invention further provides the use of the above reagent in preparing products for liver cancer detection and prognosis evaluation.
[0029] Compared with the existing GDF15 antagonists, the beneficial effects of the present invention are mainly reflected in: (1) the present invention is the first to discover that TCF19 directly inhibits the expression of GDF15 at the transcription level rather than the protein level; (2) compared with the direct preparation of GDF15 neutralizing monoclonal antibodies, providing upstream regulatory factors as target inhibitors has lower preparation technology difficulty and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 To verify the binding of TCF19 to GDF15 promoter, (A) schematic diagram of the structural fragment of GDF15 promoter, (B) detection results of the binding of TCF19 to GDF15 promoter;
[0031] Figure 2 To show the effects of overexpression and knockdown of TCF19 on the expression of GDF15 at the mRNA level, (A) Huh1 cells were transfected with small interfering RNA targeting TCF19, (B) the full-length TCF19 group (TCF19-3′FLAG) was overexpressed in Huh1 cells;
[0032] Figure 3 To show the effects of overexpression and knockdown of TCF19 on the expression of GDF15 at the protein level, (A) Huh1 cells were transfected with small interfering RNA targeting TCF19, (B) the full-length TCF19 group (TCF19-3′FLAG) was overexpressed in Huh1 cells;
[0033] Figure 4 To investigate the effect of knocking down TCF19 on the secretion level of GDF15, (A) Huh1 cells were transfected with small interfering RNA targeting TCF19, and (B) HCCLM3 cells were transfected with small interfering RNA targeting TCF19. DETAILED DESCRIPTION
[0034] In order to explain the present invention more clearly, the present invention is further described in detail below in conjunction with embodiments and with reference to the accompanying drawings. It should be understood by those skilled in the art that the content described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.
[0035] Unless otherwise specified, the reagents used in the following examples are all commercially available products.
[0036] Example 1 TCF19 binds to the GDF15 promoter via the PHD domain
[0037] Human hepatoma cell line HCCLM3 was cultured in DMEM medium (Punosai, PM150210) containing 10% FBS (VISTECH), supplemented with 100 U / mL penicillin and 100 U / mL streptomycin, at 37°C, 5% CO2 incubator. Vector control plasmid, TCF19-3'FLAG plasmid and TCF19-ΔPHD-3'FLAG plasmid were constructed according to PolyJet TM In Vitro DNA Transfection Reagent instructions, transfect plasmids, add 3.0 μg / mL Puromycin, screen and construct stable transfected cell lines, and harvest cells. According to the instructions of Sonication ChIP Kit (RK20258, ABclonal), use FLAG antibody (AE092, ABclonal) and Pierce TM Protein A / G magnetic beads (88802, Thermo) were used to enrich and extract DNA, and the concentration was determined using NanoDrop. Five pairs of primers were designed upstream of the transcription start site of the GDF15 promoter, namely GDF15-1-F / R, GDF15-2-F / R, GDF15-3-F / R, GDF15-4-F / R and GDF15-5-F / R.
[0038] GDF15-1-F: 5'-GCACCCTGCTTAGACTGGAA-3';
[0039] GDF15-1-R: 5′-CACAGGGCCAGACACATAGG-3′;
[0040] GDF15-2-F: 5′-TCCTATGTGTCTGGCCCTGT-3′;
[0041] GDF15-2-R: 5′-ATGTGTCATGCCTCTCTGCC-3′;
[0042] GDF15-3-F: 5′-CCTGGTGAGGAAACAGGCAT-3′;
[0043] GDF15-3-R: 5′-AGGAGAACGGGCTAGATGGA-3′;
[0044] GDF15-4-F: 5′-ATCAAGGTTGCCCTTCCTGG-3′;
[0045] GDF15-4-R: 5′-TGCCCATGGGATTTCCTCTC-3′;
[0046] GDF15-5-F: 5'-AGCCTTTGACCCAACCAAA-3';
[0047] GDF15-5-R: 5'-ATGAGGACACCATTCCAGCC-3'.
[0048] The internal reference primers are:
[0049] GAPDH-1-F: 5'-GGTGGTCTCCTCTGACTTC-3';
[0050] GAPDH-1-R: 5'-CTCTTCCTCTTGTGCTCTTG-3'.
[0051] Using CFX Connect TM Real-Time PCR Detection System (BIO-RAD) and ChamQUniversal SYBR qPCR Master Mix (Q711, Vazyme) were used to detect the expression of enriched DNA. The conditions for fluorescence quantitative PCR were: 95°C pre-denaturation for 3 min, 95°C denaturation for 10 s, 60°C annealing for 20 s, 72°C extension for 15 s, a total of 40 cycles, and the cycle number Ct value was obtained. According to Percentage of Input = 5% × 2 (Ct (Input Sample) – Ct (IP Sample)), after statistical analysis, Graphpad Prism10 was used to draw the graph, as shown in the figure. Figure 1 .
[0052] The results showed that compared with the Vector control group and the TCF19-ΔPHD-3'FLAG truncation group, the TCF19 full-length overexpression group (TCF19-3'FLAG) was significantly enriched in the GDF15 promoter. This example shows that TCF19 binds to the GDF15 promoter through the PHD domain.
[0053] Example 2 TCF19 positively regulates GDF15 expression at the mRNA level
[0054] Human hepatoma cell line Huh1 was cultured in DMEM medium (Punosai, PM150210) containing 10% FBS (VISTECH), supplemented with 100 U / mL penicillin and 100 U / mL streptomycin, at 37°C, 5% CO2 incubator. Vector control plasmid and TCF19-3'FLAG plasmid were constructed according to PolyJet TMIn Vitro DNA Transfection Reagent instructions: transfect plasmid, add 0.8μg / mL Puromycin, successfully screen and construct Huh1 stable transfected cell lines, and harvest cells. According to the instructions of LipofectamineRNAiMAX (Thermo), Huh1 cells were transfected with small interfering RNA targeting TCF19, and the cells were harvested after 48h of culture.
[0055] siTCF19-1: 5'-GGUCACAGGCUGGAAUUGA-3';
[0056] siTCF19-2: 5′-CACAACGCAAUCGGAGGAAAU-3′;
[0057] The collected cells were used to extract total RNA from the cells using Trizol (#9109, Takara), and the concentration was determined using NanoDrop. 1 μg of RNA was reverse transcribed using a reverse transcription kit (R323-01, Vazyme) to obtain cDNA. The fluorescence quantitative PCR system included 5 μL ChamQ Universal SYBR qPCR Master Mix (Q711, Vazyme), 0.2 μL cDNA, 0.2 μL F / R primers, and ddH2O was used to fill the mixture to 10 μl. CFX ConnectTM Real-Time PCR DetectionSystem (BIO-RAD) was used for quantitative detection, GAPDH was used as an internal reference, and 2 -ΔΔCt The relative expression levels of TCF19 and GDF15 were calculated by the NCBI BLAST method. TCF19 and GDF15 detection primers (TCF19-F, TCF19-R, GDF15-F, GDF15-R) and internal reference primers (GAPDH-F, GAPDH-R) were designed:
[0058] TCF19-F: 5'-CCATGCTGCCCTGCTTCCAAC-3';
[0059] TCF19-R: 5'-CTGCTGTGGTCTTCCAGGCTG-3';
[0060] GDF15-F: 5'-GTTGCACTCCGAAGACTCC-3';
[0061] GDF15-R: 5'-GAGAGATACGCAGGTGCAGG-3';
[0062] GAPDH-F: 5'-TGCACCACCAACTGCTTAGC-3';
[0063] GAPDH-R: 5'-GGCATGGACTGTGGTCATGAG-3'.
[0064] Results Figure 2 , overexpression and knockdown of TCF19 in cells can promote and inhibit GDF15 transcription. This example shows that TCF19 positively regulates GDF15 expression at the mRNA level.
[0065] Example 3 TCF19 positively regulates GDF15 expression at the protein level
[0066] The collected Huh1 stable cells and Huh1 cells transfected with siRNA were lysed with RIPA (89901, Thermo) and lysed with Pierce TM BCA Protein Assay Kits (A55864, Thermo) were used for protein quantification and Western blot was performed.
[0067] Results Figure 3 , when cells overexpress TCF19, the protein expression level of GDF15 increases; when TCF19 is knocked down, the protein expression level of GDF15 decreases. This example shows that TCF19 positively regulates the expression of GDF15 at the protein level.
[0068] Example 4 TCF19 positively regulates the secretion level of GDF15
[0069] Huh1 and HCCLM3 cells were transfected with small interfering RNA targeting TCF19, and the cell culture supernatant was collected after culturing for 72 h and 96 h, respectively, and diluted 5 times and 10 times, respectively. The GDF15 content in the supernatant was detected according to the instructions of Human GDF15 (Growth Differentiation Factor 15) ELISA Kit (EH0150, FineTest).
[0070] Results Figure 4 , knocking down TCF19 in Huh1 and HCCLM3 cells can significantly inhibit the secretion level of GDF15. This example shows that TCF19 positively regulates the expression of GDF15 at the protein level.
[0071] GDF15 is a stress response cytokine and a distant relative of the transforming growth factor β superfamily. The serum GDF15 level in healthy people is low, while under pathological conditions, GDF15 expression is upregulated with injury, inflammation, and tumor formation. There is evidence that serum GDF15 levels increase significantly with the severity of lobular inflammation and hepatocyte ballooning. GDF15 is highly expressed in liver cancer tissues and serum GDF15 levels are associated with HCC staging. In addition, GDF15 is also a tumor-derived immunosuppressive molecule and an important target for HCC cancer immunotherapy.
[0072] This application first discovered and clarified the direct regulation of GDF15 transcription by histone reader protein TCF19, that is, TCF19 can promote GDF15 transcription in tumor cells, thereby increasing its secretion level. Furthermore, the development of a GDF15 inhibitor targeting TCF19 can inhibit the transcription of GDF15 in tumor cells, thereby reducing GDF15 secretion and inhibiting tumor cell proliferation, which has broad application prospects.
[0073] It should be noted that the above experiments only list several specific examples of the present invention. Obviously, there are many variations of the present invention. All variations that can be directly derived or associated with the contents disclosed by ordinary technicians in this field should be considered to be within the scope of protection of the present invention.
Claims
1. Use of a TCF19 inhibitor in the preparation of a drug for inhibiting the expression of the GDF15 gene, wherein the TCF19 inhibitor uses TCF19 as a target to inhibit the expression of the GDF15 gene at the transcriptional level.
2. The use according to claim 1, characterized in that: TCF19 binds to the GDF15 promoter via its PHD domain.
3. The use according to claim 1, characterized in that: TCF19 positively regulates the expression of GDF15 gene at the mRNA level and protein level.
4. The use according to claim 3, characterized in that: Overexpression and knockdown of TCF19 in cells can promote and inhibit GDF15 transcription, respectively; when cells overexpress TCF19, the protein level of GDF15 increases, and when TCF19 is knocked down, the protein expression level of GDF15 decreases.
5. Use of a GDF15 inhibitor targeting TCF19 in the preparation of a drug for treating liver cancer, wherein the GDF15 inhibitor targeting TCF19 inhibits the transcription of GDF15 in tumor cells by targeting TCF19.
6. The use according to claim 5, characterized in that: TCF19 binds via the PHD domain GDF15 promoter.
7. The use according to claim 5, characterized in that: TCF19 positively regulates the expression of GDF15 gene at the mRNA level and protein level.
8. A reagent for detecting the binding of TCF19 and GDF15, comprising the following detection primers: GDF15-1-F: 5'-GCACCCTGCTTAGACTGGAA-3'; GDF15-1-R: 5′-CACAGGGCCAGACACATAGG-3′; GDF15-2-F: 5′-TCCTATGTGTCTGGCCCTGT-3′; GDF15-2-R: 5′-ATGTGTCATGCCTCTCTGCC-3′; GDF15-3-F: 5′-CCTGGTGAGGAAACAGGCAT-3′; GDF15-3-R: 5′-AGGAGAACGGGCTAGATGGA-3′; GDF15-4-F: 5′-ATCAAGGTTGCCCTTCCTGG-3′; GDF15-4-R: 5′-TGCCCATGGGATTTCCTCTC-3′; GDF15-5-F: 5'-AGCCTTTGACCCAACCAAA-3'; GDF15-5-R: 5'-ATGAGGACACCATTCCAGCC-3'.
9. The reagent according to claim 8, characterized in that Also included are internal reference primers: GAPDH-1-F: 5'-GGTGGTCTCCTCTGACTTC-3'; GAPDH-1-R: 5'-CTCTTCCTCTTGTGCTCTTG-3'.
10. Use of the reagent according to claim 8 or 9 in the preparation of products for liver cancer detection and prognosis assessment.
Citation Information
Cited By
Application of TCF19 inhibiting reagent in preparation of medicine for treating lung adenocarcinoma
CN120624656A
